Project Grant R01DE032676
Award Date
7/5/24
Completion Date
6/30/27
Dollars Obligated
$2.4M
Funding Federal Agency
National Institute of Neurological Disorders and Stroke
Awarding Federal Agency
National Institute of Dental and Craniofacial Research
Awardee
Duke University (TP7EK8DZV6N5)
Federal Grant Program
93.279
Assistance Type
Project Grant
Place of Performance
Durham, NC 27710, USA
Similar Awards
This federal Project Grant award of $1,220,798 from the National Institute of Dental and Craniofacial Research (NIDCR), under the Oral Diseases and Disorders Research (CFDA 93.121) program, supports research to quantify nociceptive versus pain sensitivity in individuals with temporomandibular disorders (TMD). The project aims to develop a novel nociceptive-specific heating (NOSH) protocol to objectively measure nociceptor sensitivity and distinguish it from pain perception. The research will...
This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $444,125 to Duke University to conduct research exploring the role of the LRRC55 protein in chronic pain pathways. The goal is to determine if LRRC55, a regulatory subunit of the BK potassium channel, can serve as a novel target for treating chronic pain, particularly mechanical pain, without the side effects associated...
This $838,750 project grant, awarded by the National Institute of Neurological Disorders and Stroke (NINDS) under the Drug Use and Addiction Research Programs (CFDA 93.279), aims to investigate the role of the GCH1 gene and its encoded enzyme GTP cyclohydrolase 1 (GTPCH1) in chronic orofacial neuropathic pain.
The key objectives are to: 1) Evaluate how orofacial neuropathic pain impacts the expression of GCH1 in the trigeminal ganglia and central pain and reward-related pathways, and 2)...
This $620,278 federal Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, supports research to investigate the molecular basis for using S1P receptor 1 (S1PR1) antagonists to treat the comorbid conditions of migraine and temporomandibular disorders (TMDs). The research team, led by the University of Maryland, Baltimore, will use a...
This $2,569,851 federal Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Drug Abuse and Addiction Research Programs (CFDA 93.279), supports research to investigate how the PD-L1/PD-1 immune checkpoint pathway controls physiological and pathological pain, as well as opioid analgesia, through neuronal, immune, and glial mechanisms. The project aims to validate the actions of PD-L1 and the checkpoint inhibitor nivolumab on neuroinflammation...
This $5,037,022 project grant from the National Institutes of Health's National Institute of Neurological Disorders and Stroke will support the development of novel single-cell technologies called "Raman2omics" to map pain-associated genes and cells across the lifespan. Funded under the Drug Abuse and Addiction Research Programs, the grant to the Massachusetts General Hospital aims to apply Raman2omics to systematically investigate genes and cells associated with postoperative pain...
The National Institute of Neurological Disorders and Stroke (NINDS) awarded a $1,511,970 Project Grant (CFDA 93.279 - Drug Use and Addiction Research Programs) to Saint Louis University to develop selective GPR34 antagonists for the treatment of neuropathic pain. The project aims to establish the biological rationale and infrastructure for advancing novel non-opioid based GPR34 antagonists as potential drug candidates for neuropathic pain, which affects 15-20 million people in the U.S. The...
This federal Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Drug Use and Addiction Research Programs (CFDA 93.279), is supporting research to develop novel methods for selectively stimulating nociceptors and measuring nociceptive-specific brain activity in both pain-free individuals and patients with fibromyalgia. The $2,314,276 award to Emory University aims to advance the use of quantitative sensory testing, functional MRI, and...
This federal Project Grant award from the National Institute of Dental and Craniofacial Research (NIDCR), under the Oral Diseases and Disorders Research program (CFDA 93.121), provides $589,725 to the University of Southern California (USC) to conduct research on mapping the molecular, cellular, and innervation changes in the temporomandibular joint (TMJ) that occur with osteoarthritis (OA).
The key goals of this 5-year grant are to: 1) Create a comprehensive single-cell transcriptomic and...
This National Institutes of Health (NIH) National Institute on Drug Abuse (NIDA) project grant award, with CFDA number 93.279 for Drug Use and Addiction Research Programs, provides $154,568 in funding to The Washington University in St. Louis to conduct research on the role of endogenous opioids in the dorsal raphe nucleus (DRN) and their contribution to motivational and affective behavioral dysfunction during chronic pain. The 3.5-year project, running from June 2025 to December 2028, aims...